



Epidemiological study on Oropharyngeal Candidiasis and results on miconazole MBT* compliance were presented at the 51st ASTRO Annual Meeting

Paris, November 5, 2009 – Results on epidemiologic study on OroPharyngeal Candidiasis (OPC) in oncology were presented at the 51st ASTRO (American Society for Therapeutic Radiology and Oncology) Meeting in Chicago (From November 1st to November 5th).

Pr David Azria (Anticancer Center Montpellier) has presented the data collected in 35 public and private oncology centers.

This study of 2027 cancer patients revealed a 10% prevalence (total number of cases of a disease in a given population at a specific time) of OPC. Patients receiving a combination of chemotherapy and radiotherapy are more likely to suffer from OPC (22%) than those receiving chemotherapy or radiotherapy alone. Highest prevalence was seen in patients with head and neck cancer (30%). Local treatments, such as miconazole MBT^ù, amphotericin B or nystatin mouthwashes are usually prescribed, as per treatment guidelines. Treatment compliance is strongly increased with drugs administered once daily (miconazole MBT) versus treatments with multiple daily dosing (amphotericin B or nystatin mouthwashes).

* *miconazole MBT: Mucoadhesive Buccal Tablet, Loramyc[®] in Europe*

About OPC

Also known as thrush is an oral fungal infection most common in individuals with weakened immune systems – particularly those with HIV/AIDS and those undergoing cancer treatments. OPC is a disruptive condition that results in lesions and inflammation in the mouth, and includes symptoms such as soreness, burning and/or altered taste.

About ASTRO

Radiation oncologists, radiation oncology nurses, medical physicists, radiation therapists, dosimetrists and biologists comprise ASTRO's more than 10,000 members, making it the largest radiation oncology organization of its kind. These medical professionals, found at hospitals and cancer treatment centers around the globe, make up the radiation therapy treatment teams that are critical in the fight against cancer. These teams, which often include a nutritionist and a social worker, treat more than 1 million cancer patients each year.

About BioAlliance Pharma

As a preferred partner for hospital-based specialists, BioAlliance Pharma is a company which develops and markets innovative products in France, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, our targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs.

For more information, visit the BioAlliance Pharma web site at <http://www.bioalliancepharma.com>.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website (<http://www.amf-france.org>) or on BioAlliance Pharma S.A.'s website (<http://www.bioalliancepharma.com>).

BioAlliance Pharma SA

Dominique Costantini MD, President and CEO

Tel.: +33 1 45 58 76 01

dominique.costantini@bioalliancepharma.com

Nicolas Fellmann, CFO

Tel.: +33 1 45 58 71 00

nicolas.fellmann@bioalliancepharma.com

ALIZE RP

Caroline Carmagnol

Tel.: +33 6 64 18 99 59

caroline@alizerp.com